First Lassa Fever Vaccine Wins EMA PRIME Designation; Advanced Therapies Dominate 2024 Entries

Two investigational products have made it onto the European Medicines Agency’s priority medicines scheme so far this year. Meanwhile, of the 14 products that entered the scheme last year, six were advanced therapies.